Status:
TERMINATED
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Post-ERCP Acute Pancreatitis
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic technique utilized to diagnose and treat pathologic conditions involving the ducts draining the liver and pancreas. Post...
Eligibility Criteria
Inclusion
- Age\<=18 years
- Undergoing ERCP (defined as cannulation of the major or minor papilla) for any indication
Exclusion
- Age\>18
- Pancreatitis within the 72 hours preceding ERCP
- Allergy or hypersensitivity to Aspirin or NSAID medications
- Pregnancy or breastfeeding mother
- Cr \>1.4
- Gastrointestinal hemorrhage in preceding 72 hours
- Heart disease reliant upon a patient ductus arteriosis
- History of sickle cell disease
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2018
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT02241512
Start Date
September 1 2014
End Date
September 1 2018
Last Update
February 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Medical Center of Dallas
Dallas, Texas, United States, 75235